Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Merck & Co., Inc. · PHARMACEUTICAL PREPARATIONS · Now $115.17
+7.2% in 3d after detection
Post-detection moves
1h
—
1d
-1.1%
3d
+7.2%
7d
+3.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS